InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.195 0.02 (9.30%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$25 Notification regarding unquoted securities - AGN 10 Jun 2022 8:22AM $0.390 $0.195 fallen by 50%
$25 Cleansing Notice 10 Jun 2022 8:22AM $0.390 $0.195 fallen by 50%
$25 Application for quotation of securities - AGN 10 Jun 2022 8:22AM $0.390 $0.195 fallen by 50%
$25 Proposed issue of securities - AGN 3 Jun 2022 9:45AM $0.485 $0.195 fallen by 59.79%
$25 Proposed issue of securities - AGN 3 Jun 2022 9:45AM $0.485 $0.195 fallen by 59.79%
$25 Argenica Successfully Completes $5.5m Placement 3 Jun 2022 9:45AM $0.485 $0.195 fallen by 59.79%
$25 Trading Halt 1 Jun 2022 9:20AM $0.485 $0.195 fallen by 59.79%
$25 Successful Completion of Final Pre-Clinical PK Study 19 May 2022 9:05AM $0.490 $0.195 fallen by 60.20%
$25 GLP Safety Studies Successfully Completed 5 May 2022 9:11AM $0.440 $0.195 fallen by 55.68%
$25 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2022 9:18AM $0.450 $0.195 fallen by 56.67%
$25 Maximum Tolerated Dose Successfully Established in Studies 26 Apr 2022 9:14AM $0.530 $0.195 fallen by 63.21%
$25 Initial Director's Interest Notice 4 Apr 2022 8:16AM $0.660 $0.195 fallen by 70.45%
$25 Argenica Appoints CEO Dr Liz Dallimore Managing Director 4 Apr 2022 8:16AM $0.660 $0.195 fallen by 70.45%
$25 Positive Preclincal Data on Efficacy in New Indication 30 Mar 2022 8:26AM $0.560 $0.195 fallen by 65.18%
$25 Peer Reviewed Paper Published on Preclinical Study 21 Mar 2022 8:23AM $0.560 $0.195 fallen by 65.18%
$25 Investor Presentation 16 Mar 2022 8:24AM $0.575 $0.195 fallen by 66.09%
$25 Change of Director's Interest Notice 28 Feb 2022 8:03AM $0.645 $0.195 fallen by 69.77%
$25 Successful Completion of Final GLP Genotoxicity Studies 24 Feb 2022 8:09AM $0.630 $0.195 fallen by 69.05%
$25 Half Yearly Report and Accounts 22 Feb 2022 5:22PM $0.675 $0.195 fallen by 71.11%
$25 Quarterly Activities/Appendix 4C Cash Flow Report 27 Jan 2022 8:13AM $0.740 $0.195 fallen by 73.65%
$25 Preliminary Pre-Clinical Tox Studies Successfully Completed 24 Jan 2022 8:15AM $0.860 $0.195 fallen by 77.33%
$25 Argenica Appoints Head of Clinical Development 13 Jan 2022 9:48AM $0.840 $0.195 fallen by 76.79%
$25 Notification regarding unquoted securities - AGN 13 Jan 2022 9:43AM $0.840 $0.195 fallen by 76.79%
$25 Application for quotation of securities - AGN 31 Dec 2021 8:17AM $0.800 $0.195 fallen by 75.63%
$25 Application for quotation of securities - AGN 17 Dec 2021 9:51AM $0.750 $0.195 fallen by 74%

226 - 250 of 292 results

Page 10 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.